Pfizer Global Medical Grants – Increase Awareness & Understanding of Emerging Hemophilia Treatment Options
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Friday 20th, September 2024
External Deadline: Monday 30th, September 2024
Description
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: June 26, 2024
Geographic Scope: Global (excluding United States)
Clinical Area: Hemophilia
Link to full RFP: Increase Awareness & Understanding of Emerging Hemophilia Treatment Options
Application Due Date: Rolling due dates – please see RFP for details
| Application
Submitted by |
Decision Notification
Date |
Program Start Date
must be after |
| 31 July 2024 | 4 September 2024 | 15 September 2024 |
| 30 September 2024 | 4 November 2024 | 15 November 2024 |
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on:
- – Educating on the evolving treatment landscape (i.e. genetic medicine, rebalancing strategies) for hemophilia to improve the understanding of these novel approaches and their potential clinical applicability.
- – Discussing shared decision making (SDM) and practical approaches on how SDM can be incorporated into hemophilia patient care
- – Educating on the benefits of omnichannel healthcare strategies which can provide a seamless, personalized service and patient care experience
- – Sharing knowledge and best practices (i.e. staff training, SOP, follow-up care) on how Hemophilia Treatment Centers (HTCs) and multidisciplinary team are preparing for novel therapies in development
– Advancing patient education on the evolving hemophilia treatment landscape and improving patient’s empowerment and ability to make informed decisions about their care - Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Amanda Stein, Grant Officer (amanda.j.stein@pfizer.com).